



Attorney Docket No.: 10070.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of: Jesper Vind

Confirmation No: 9234

OCT 09 2002

Serial No.: 10/004,993

Group Art Unit: 1645

Filed: December 4, 2001

Examiner: To be assigned

TECH CENTER 1600/2900

For: Method For Producing a Polynucleotide Library

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 02/24953 A1
2. WO 99/29902
3. WO 01/34835 A2
4. WO 00/00632
5. Volkov et al, "Recombination and Chimeragenesis by in vitro heteroduplex formation and in vivo repair", 1999 Oxford University Press Nucleic Acids Research, 1999 Vol. 27, No. 18
6. Cami et al, "Correction of complex heteroduplexes made of mouse H-2 gene sequences in Escherichia coli K-12", Proc. Natl. Acad. Sci. USA Vol. 81, pp. 503-507, January 1984 genetics
7. Chang et al, "Recombination following transformation of Escherichia coli by heteroduplex plasmid DNA molecules", Gene, 29 (1984) 255-261 Elsevier

8. Abastado et al, "Processing of complex heteroduplexes in Escherichia coli and Cos-1 monkey cells", Proc. Natl. Acad. Sci. USA Vol. 81, pp. 5792-5796, September 1984 Genetics

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: October 2, 2002



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097



1645

PATENT 11 HB

Attorney Docket No.: 10070.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jesper Vind

Confirmation No: 9234

Serial No.: 10/004,993

Group Art Unit: 1645

Filed: December 4, 2001

Examiner: To be assigned

For: Method For Producing a Polynucleotide Library

RECEIVED 10/31/02
OCT 09 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


- 1. Information Disclosure Statement
- 2. Form PTO-1449
- 3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD
Commissioner for Patents
Washington, DC 20231

On October 2, 2002.

Lourdes Ayala
(name of person mailing paper)


(signature of person mailing paper)